Viken, Sweden – October 25, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Adriano Chiò, of the University of Torino and the Città della Salute e della Scienza Hospital as the fourth member of its newly formed Scientific Advisory Board. Adriano Chiò is a neurologist
Viken – October 11, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Jeremy Shefner, MD, PhD at the Gregory W. Fulton ALS & Neuromuscular Disease Center, the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA as the third member of its newly-formed
Viken – September 26, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Caroline Ingre, MD, PhD senior consultant neurology and Head of ALS at Karolinska University Hospital and Karolinska Institute as the second member of its newly-formed Scientific Advisory Board. Dr. Ingre runs the ALS clinic at
Viken – September 19, 2023 – Today, Swedish biopharmaceutical company TikoMed AB announced the formation of its Scientific Advisory Board (SAB). The SAB will work cohesively with management to advance the company’s clinical development of ILB, TikoMeds drug in Phase 2 development in ALS. The board will integrate highly experienced
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies Viken, Sweden – 13th September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company’s lead drug candidate ILB® to: inhibit infection
Viken, Sweden – 7th September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company’s lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian)